Skip to content
Calculator
Analysis

The peptide drug pipeline in 2026

Last updated: October 27, 2026 · 11 min read · By the Grey Peptides Editorial Board

A focused scientist holding a pipette in a laboratory environment
Photo by ThisIsEngineering on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Our encyclopedia records ten US approvals of peptides and close relatives so far in 2026, including two peptide tablets: icotrokinra for psoriasis and enlicitide for cholesterol.
  • The pipeline behind them is large and lopsided: 331 INN-named peptides have reached phase 2 or later, but only 97 have a trial running now, and obesity drugs dominate the late stage.
  • The next big decisions are CagriSema, with an FDA decision anticipated by late 2026, and retatrutide, which Lilly plans to submit for US approval in early 2027. Neither is approved; Lilly states retatrutide cannot be legally sold or marketed for human use.

This year's approvals

Our encyclopedia records ten US approvals so far this year of peptides and their close relatives 1:

2026 dateDrugMoleculeApproved for
February 27Navepegritide (Yuviwel)Peptide conjugateachondroplasia (accelerated approval)
March 17Icotrokinra (Icotyde)Peptideplaque psoriasis, as a daily tablet
March 26Insulin icodec (Awiqli)Proteintype 2 diabetes, once weekly
April 1Orforglipron (Foundayo)Small moleculechronic weight management, as a daily pill
May 22Bulevirtide (Hepcludex)Peptidechronic hepatitis D
July 15Enlicitide (Lipfendra)Peptidehigh LDL cholesterol, as a daily tablet
August 19Garetosmab (Pasatru)Antibodyfibrodysplasia ossificans progressiva
August 28Rusfertide (Mimrylo)Peptideerythrocytosis in polycythaemia vera
September 11Apitegromab (Isembyld)Antibodyspinal muscular atrophy, alongside SMN2 therapy
September 23Insulin efsitora alfa (Onswik)Proteintype 2 diabetes, once weekly

Three things stand out. First, two of the peptides are tablets: icotrokinra, approved for moderate-to-severe plaque psoriasis in adults and adolescents, and enlicitide, approved to lower LDL cholesterol 1. Second, the list is not only peptides: orforglipron, Lilly's weight-loss pill, is a small molecule that acts on the same receptor as the GLP-1 peptides, and two of the approvals are antibodies 1. Our guide to what makes a peptide a peptide explains the difference. Third, several approvals are for rare diseases, such as achondroplasia, fibrodysplasia ossificans progressiva and spinal muscular atrophy 1.

The oral peptide turn

Two of this year's peptide approvals are tablets. Oral semaglutide came earlier, paired with an absorption enhancer, SNAC; its label estimates that only about 0.4% to 2% of a dose reaches the blood and requires it to be taken on an empty stomach with no more than 4 ounces of water, 30 minutes before food 2.

Icotrokinra is a 13-amino-acid peptide with a disulfide-bridged ring and non-natural residues that blocks the interleukin-23 receptor; enlicitide is a macrocyclic (ring-shaped) peptide that blocks PCSK9 1. Both were approved for common chronic diseases, psoriasis and high cholesterol 1. Orforglipron, approved the same spring, shows a different strategy: a small molecule that acts on the GLP-1 receptor 1.

How big is the pipeline?

Counting a pipeline depends on what you count. We use the international nonproprietary names (INNs) that the World Health Organization assigns to drugs, which follow naming stems: peptides usually end in '-tide', gonadotropin-releasing hormone drugs in '-relin' or '-relix', vasopressin analogues in '-pressin'. Our pipeline tracker takes every INN-named peptide in the ChEMBL database whose highest recorded phase is 2 or more, then checks ClinicalTrials.gov for what is running now 3.

As of October 1, 2026, that gives 331 molecules: 205 whose furthest point is phase 2, 48 that have reached phase 3 and 78 that have been approved somewhere 3. 267 carry the '-tide' stem. But only 97 have at least one active registered study, 1225 studies in all, and for most of the rest the trail has gone cold 3. Among the molecules with active studies, the most advanced running trial is phase 3 for 33, phase 4 for 28, phase 2 for 25 and phase 1 or earlier for 4 3.

Our broader peptide registry, which also includes natural peptides and compounds without INNs, holds 935 rows: 144 approved, 45 at phase 3, 192 at phase 2 and 12 at phase 1, with the rest endogenous peptides or compounds whose development status is unknown 4.

What the active pipeline is aiming at

ChEMBL records a mechanism for most molecules. Among the 97 peptides with an active study, the mechanisms recorded most often are below; 55 have no mechanism recorded 3.

Mechanism recorded in ChEMBLMolecules with active studies
Glucagon-like peptide 1 receptor agonist9
Parathyroid hormone receptor agonist4
Oxytocin receptor agonist2
Heat-stable enterotoxin receptor agonist2
C-X-C chemokine receptor type 4 antagonist2
Melanocortin receptor 4 agonist2
Gastric inhibitory polypeptide receptor agonist2
Vasopressin receptor agonist2
Glucagon receptor agonist2

The table shows which mechanisms ChEMBL records most often among the peptides with active studies 3.

The obesity race

Most of the money and attention in late-stage peptide development is in obesity and diabetes. The table lists the leading candidates in our encyclopedia, with the number of phase 3 studies registered for each on ClinicalTrials.gov 5 1:

CompoundHow it worksRegistered phase 3 studiesWhere it stands
RetatrutideGIP, GLP-1 and glucagon receptor agonist14Five positive phase 3 trials; Lilly plans a US filing in Q1 2027
CagriSemaSemaglutide plus the amylin analogue cagrilintide19Filed with FDA December 2025; decision anticipated by late 2026
Maridebart cafraglutideGLP-1 agonist peptides on a GIP-blocking antibody12Phase 3 MARITIME programme
SurvodutideGLP-1 and glucagon receptor agonist12Phase 3 in obesity and liver disease
EloralintideAmylin receptor agonist7Five phase 3 ENLIGHTEN trials registered from December 2025
MazdutideGLP-1 and glucagon receptor agonist11Approved in China June 27, 2025; not in the US
EcnoglutideGLP-1 receptor agonist7Approved in China in 2026; not in the US
AmycretinGLP-1 and amylin receptor agonist0Phase 1 and 2 published; no registered phase 3 counted
PetrelintideAmylin receptor agonist3Phase 2 ZUPREME 1 published

Retatrutide is the most advanced of the next generation. It activates three receptors, GIP, GLP-1 and glucagon, and Lilly reported in July 2026 that it had five positive phase 3 studies; in TRIUMPH-2, adults with obesity or overweight and type 2 diabetes on the highest dose lost up to an average of 20.8% of body weight at 80 weeks. Lilly says it plans to submit retatrutide for US approval in the first quarter of 2027 6. Until then it is investigational: Lilly's own release states that retatrutide cannot be legally sold or marketed for human use 6.

CagriSema, Novo Nordisk's weekly combination of semaglutide and the amylin analogue cagrilintide, is the nearest decision. Novo submitted it to FDA in December 2025, on the REDEFINE 1 and 2 trials, and anticipates a decision by late 2026 7. In February 2026 Novo reported that REDEFINE 4 did not show non-inferiority to tirzepatide: 23.0% against 25.5% weight loss at 84 weeks in the efficacy estimand 7 8.

Behind them come Amgen's maridebart-cafraglutide, which hangs two GLP-1 peptides on an antibody that blocks the GIP receptor; Boehringer Ingelheim and Zealand's survodutide; and a wave of amylin drugs, eloralintide, petrelintide and the dual amylin and GLP-1 agonist amycretin 1. China has moved faster on two: mazdutide was approved there in June 2025 and ecnoglutide in 2026, neither with a US application 1.

Beyond weight loss

The rest of the pipeline is more varied than the headlines suggest. This year's approvals include rusfertide, a hepcidin mimetic that controls red cell production in polycythaemia vera; bulevirtide, which blocks the receptor hepatitis D uses to enter liver cells; and navepegritide, a long-acting form of the growth peptide CNP for children with achondroplasia 1. Radioligands, peptides or peptide-like molecules that carry radioactive atoms to tumours, keep expanding: Pluvicto's current label (effective August 12, 2026) covers earlier-stage disease as well as the original indication, and our entry on vipivotide tetraxetan sets out the trials behind it 1.

Gut peptides are another cluster. Glepaglutide met its primary endpoint in short bowel syndrome, and apraglutide is in development for the same condition 1. Not every story ends well: larazotide, once the leading drug candidate for coeliac disease, had its phase 3 trial terminated by its sponsor 1. Liver disease is a growing target, with pemvidutide given Breakthrough Therapy designation for MASH in January 2026 and survodutide in phase 3 for the same condition 1.

Readouts due this quarter

Each molecule in our pipeline tracker carries the expected primary completion date of its next registered study. Between October and December 2026, 36 molecule-study pairs have a readout due; the phase 2 and 3 studies among them are below 3. A primary completion date is the sponsor's estimate of when the last participant is measured, not a promise that results will be published then, and 5 registered readouts in the tracker are already overdue without an update 3.

ExpectedPeptidePhaseStudy
2026-10oxytocinPhase 2NCT06036004: Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus
2026-10retatrutidePhase 3NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moder
2026-10-01dulaglutidePhase 3NCT06257966: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination
2026-10-15semaglutidePhase 2NCT07505303: MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
2026-10-15vipivotide tetraxetanPhase 2NCT06894511: An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With
2026-10-29pasireotidePhase 2NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
2026-10-31setmelanotidePhase 2NCT06772597: A Study of Setmelanotide in Patients With Prader-Willi Syndrome
2026-11degarelixPhase 2NCT03951831: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Ca
2026-11goserelinPhase 2NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
2026-11lanreotidePhase 3NCT05050942: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GE
2026-11bulevirtidePhase 2NCT07142811: A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
2026-11-02gallium oxodotreotidePhase 2NCT05691465: Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatat
2026-11-11triptorelinPhase 3NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less I
2026-11-13olatorepatidePhase 2NCT07431086: Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
2026-11-30ecnoglutidePhase 2NCT07553299: A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participant
2026-12-30gozetotidePhase 2NCT06145633: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistan
2026-12-31anamorelinPhase 3NCT03637816: Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lun

Who leads

The obesity race has made two companies dominant. Eli Lilly has tirzepatide on the market, orforglipron newly approved, retatrutide heading for filing and eloralintide in phase 3; Novo Nordisk has semaglutide, CagriSema under review, amycretin in development and insulin icodec newly approved 1 6 7. Amgen, Boehringer Ingelheim with Zealand Pharma, and Roche with Zealand are the main challengers, and Chinese developers such as Innovent and Sciwind have reached approval at home first 1.

Outside obesity, smaller companies built several of this year's approvals. Icotrokinra came out of a collaboration between Johnson & Johnson and Protagonist Therapeutics, a University of Queensland spin-out 9; rusfertide, developed as PTG-300, is now marketed by Takeda 1. Ascendis built navepegritide, known in development as TransCon CNP, as a once-weekly alternative to a daily drug, and Merck's enlicitide is a macrocyclic peptide designed to be swallowed, in the PCSK9-inhibitor class 1.

What to watch next

Four events will shape the next twelve months. The FDA decision on CagriSema, anticipated by late 2026, will test whether an amylin and GLP-1 combination can win approval after trailing tirzepatide head to head 7. Lilly's planned retatrutide submission in early 2027 would bring a GIP, GLP-1 and glucagon triple agonist to review 6. Phase 3 results from the amylin drugs will show whether amylin can stand on its own as a weight-loss target. And real-world uptake of the new oral peptides will show whether patients and payers prefer a daily tablet to a weekly or monthly injection.

How to read pipeline news

Three cautions help. Databases lag. ChEMBL, which our tracker and registry draw on, records the highest phase a molecule has reached, and it can take months to catch up with an approval. As we write, it still lists 3 of this year's approvals (rusfertide, enlicitide, navepegritide) as not yet approved; our encyclopedia entries, which are checked against Drugs@FDA, are the more current source 4 1.

Phases are not probabilities. A compound in phase 3 has passed earlier tests, but phase 3 can still fail, as larazotide's and taspoglutide's did 1. Our article on elamipretide's approval shows how narrow an approval can be.

In the pipeline does not mean available. FDA says it has warned companies that illegally sold unapproved drugs containing retatrutide, among other GLP-1 drugs, falsely labelled 'for research purposes' or 'not for human consumption' 10. Those products are not approved, and Lilly states that retatrutide cannot be legally sold or marketed for human use 6. Our guide to spotting a fake certificate of analysis explains why a seller's paperwork does not close that gap.

Frequently asked questions

What new peptide drugs were approved in 2026?

Our encyclopedia records ten US approvals of peptides and close relatives so far in 2026, including icotrokinra (Icotyde) and enlicitide (Lipfendra), both tablets, plus navepegritide, bulevirtide, rusfertide and two once-weekly insulins.

When will retatrutide be approved?

It is not approved. Lilly said in July 2026 that it plans to submit retatrutide for US approval in the first quarter of 2027; a decision would follow the review.

When is the FDA decision on CagriSema?

Novo Nordisk submitted CagriSema to FDA in December 2025 and anticipates a decision by late 2026. As of October 27, 2026 it is not approved.

How many peptides are in clinical trials?

As of October 1, 2026, 331 INN-named peptides had reached phase 2 or later in ChEMBL, and 97 had at least one active study on ClinicalTrials.gov.

Sources

  1. Grey Peptides encyclopedia: approval details for each entry, checked against Drugs@FDA, EMA and company announcements with the read dates shown on each entry; rusfertide's approval date from Drugs@FDA (NDA 220605), read October 3, 2026.
  2. Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets US prescribing information, sections 2.1 and 12.3. DailyMed version 14, effective January 30, 2026; read October 27, 2026. DailyMed
  3. Grey Peptides pipeline tracker data (assets/pipeline-data.json): 331 INN-named peptides at ChEMBL phase 2 or later with live ClinicalTrials.gov status, read October 1, 2026.
  4. Grey Peptides peptide registry (assets/registry.json), 935 rows from ChEMBL, openFDA, UniProt, PubMed, PubChem and ClinicalTrials.gov, generated 2026-10-02.
  5. Grey Peptides evidence counts (_ops/evidence_counts.json): ClinicalTrials.gov studies by phase for each entry, read October 3, 2026.
  6. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. News release, July 23, 2026. Read October 3 and October 27, 2026.
  7. Novo Nordisk (the manufacturer). Form 6-K, February 23, 2026 (SEC EDGAR): REDEFINE 4 (CagriSema 23.0% vs tirzepatide 25.5% at 84 weeks, efficacy estimand; non-inferiority not achieved); CagriSema submitted to FDA in December 2025 on REDEFINE 1 and 2; decision anticipated by late 2026. Read October 27, 2026; cited without a link.
  8. Clinical Trials Arena. Novo Nordisk's CagriSema bested by Lilly's Zepbound in head-to-head trial. February 23, 2026 (trade press; filing December 2025 on REDEFINE 1 and 2, decision anticipated late 2026). Read October 3, 2026.
  9. Institute for Molecular Bioscience, University of Queensland. 'Life-changing' psoriasis pill gets FDA approval. April 24, 2026 (icotrokinra developed under a collaboration between Johnson & Johnson and UQ spin-out Protagonist Therapeutics). Read October 3 and October 27, 2026.
  10. US FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026; read October 27, 2026). FDA

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead